Alternative dosing for PPI therapy: rationale and options.
The target goal for all acid suppressive therapy is to optimize control of intragastric pH over extended periods of time. A somewhat axiomatic paradigm has been that effective control of gastric acid production is associated with optimal outcome in acid-related diseases. The proton pump inhibitor (PPI) class of therapy has shown superiority for effective control of acid and healing of related diseases. Traditional delivery of PPIs may not be a viable option for all patients. Therefore, a clear understanding of alternative dosing formulations and related efficacies is key in order for the clinician to select the most appropriate agent and strategy to optimize outcomes and cost-effectiveness for each patient.
Johnson
David A
DA
Section of Gastroenterology, Eastern Virginia School of Medicine, Norfolk, Virginia, USA.
D000863:Antacids / Q000008:administration & dosage*; D002214:Capsules; D003362:Cost-Benefit Analysis; D004305:Dose-Response Relationship, Drug; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D006801:Humans; D006863:Hydrogen-Ion Concentration / Q000187:drug effects; D007275:Injections, Intravenous; D009853:Omeprazole / Q000008:administration & dosage; D010437:Peptic Ulcer / Q000188:drug therapy; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome
D000863:Antacids; D002214:Capsules; D054328:Proton Pump Inhibitors; D009853:Omeprazole